A Phase 2/3 interventional study of Midazolam and Fentanyl/Morphine in Sedation, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 18 sites in 2 countries. Open to participants aged 28 Weeks to 44 Weeks. Per ClinicalTrials.gov, last updated 2015-08-13.
Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the safety, efficacy and pharmacokinetics (PK) of dexmedetomidine (DEX) at 3 different dose levels in infants, ages ≥28 weeks to ≤44 weeks gestational age, administered as a loading dose followed by a continuous infusion for a minimum of 6 hours and up to 24 hours in the neonatal intensive care unit (NICU), cardiac intensive care unit (CICU), or pediatric intensive care unit (PICU).
Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.
First submitted before Hospira became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age: subjects must fit into 1 of the following age ranges at screening:
Exclusion Criteria:
Neonate subjects with neurological conditions that prohibit an evaluation of sedation such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
Drug: Midazolam · Drug: Fentanyl/Morphine · Drug: Dexmedetomidine
Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
Drug: Midazolam · Drug: Fentanyl/Morphine · Drug: Dexmedetomidine
Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
Drug: Midazolam · Drug: Fentanyl/Morphine · Drug: Dexmedetomidine
Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
Drug pages: Fentanyl · Morphine
Per package insert, N-PASS scores and investigator discretion.
Also known as: Precedex
Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion
Time frame: During study drug administration (6 to 24 hours)
Percentage of Subjects Who Received Rescue Medication for Analgesia During Dexmedetomidine Infusion
Time frame: During Study drug administration (6 to 24 hours)
Total Amount of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
Time frame: During Study drug administration (6 to 24 hours)
Total Amount of Rescue Medication Fentanyl Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
Time frame: During study drug administration (6 to 24 hours)
Total Amount of Rescue Medication Morphine Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
Time frame: During study drug administration (6 to 24 hours)
Weight-adjusted Total Amount (Per kg) of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used)
Time frame: During study drug administration (6 to 24 hours)
Weight-adjusted Total Amount (Per kg) of Rescue Medication Fentanyl Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)
Time frame: During study drug administration (6 to 24 hours)
Weight-adjusted Total Amount (Per kg) of Rescue Medication Morphine Given for Analgesia During Dexmedetomidine Infusion (Among Who Used)
Time frame: During study drug administration (6 to 24 hours)
Time to Successful Extubation in DEX-exposed Subjects
Time frame: From start of DEX administration to extubation of each subject up to 7 days post-infusion
| Milestone | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| Started | 14 | 14 | 8 |
| Completed | 14 | 14 | 8 |
| Not completed | 0 | 0 | 0 |
| percentage of subjects | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| Percentage of Subjects Who Received Rescue Medication Midazolam for Sedation During Dexmedetomidine Infusion | 7.1 | 7.1 | 25 |
| percentage of subjects | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| Percentage of Subjects Who Received Rescue Medication for Analgesia During Dexmedetomidine Infusion | 35.7 | 35.7 | 75 |
| Milligram | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| Total Amount of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used) | .360 ± NA | .500 ± NA | 1.125 ± 1.4637 |
| Microgram | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| Total Amount of Rescue Medication Fentanyl Given for Sedation During Dexmedetomidine Infusion (Among Who Used) | 10.808 ± 7.1305 | 5.667 ± 3.5119 | 9.522 ± 7.5131 |
| milligram | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| Total Amount of Rescue Medication Morphine Given for Sedation During Dexmedetomidine Infusion (Among Who Used) | — | 0.275 ± 0.0354 | 0.400 ± 0.1732 |
| milligrams/Kg | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| Weight-adjusted Total Amount (Per kg) of Rescue Medication Midazolam Given for Sedation During Dexmedetomidine Infusion (Among Who Used) | 0.100 ± NA | 0.152 ± NA | 0.318 ± 0.4133 |
| microgram/Kg | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| Weight-adjusted Total Amount (Per kg) of Rescue Medication Fentanyl Given for Analgesia During Dexmedetomidine Infusion (Among Who Used) | 5.137 ± 6.3696 | 1.863 ± 0.8761 | 2.725 ± 2.1383 |
| milligram/Kg | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| Weight-adjusted Total Amount (Per kg) of Rescue Medication Morphine Given for Analgesia During Dexmedetomidine Infusion (Among Who Used) | — | 0.125 ± 0.0348 | 0.109 ± 0.0540 |
| hour | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| Time to Successful Extubation in DEX-exposed Subjects | 22.9 (4.467 to 100.67) | 49.3 (33.167 to 79.583) | 23.7 (4.667 to 67.333) |
Collected over Start of study drug administration until 7 days following the start of study drug. Serious adverse events collected from signing of informed consent until 7 days following start of study drug administration or hospital discharge (whichever comes first).. Non-serious events are listed at a 2.8% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dexmedetomidine 0.05 mcg/kg | — | 0/14 (0%) | 7/14 (50%) |
| Dexmedetomidine 0.1 mcg/kg | — | 1/14 (7.1%) | 9/14 (64.3%) |
| Dexmedetomidine 0.2 mcg/kg | — | 0/8 (0%) | 6/8 (75%) |
| Event | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| BradycardiaCardiac disorders | 0/14 | 1/14 | 0/8 |
| Cardio-respiratory arrestCardiac disorders | 0/14 | 1/14 | 0/8 |
| Oxygen saturation decreasedInvestigations | 0/14 | 1/14 | 0/8 |
| Event | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg |
|---|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 0/14 | 0/14 | 3/8 |
| AngerPsychiatric disorders | 0/14 | 3/14 | 3/8 |
| Plueral effusionRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 2/8 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/14 | 3/14 | 0/8 |
| Blood potassium decreasedInvestigations | 2/14 | 0/14 | 0/8 |
| Shunt stenosisInjury, poisoning and procedural complications | 0/14 | 0/14 | 1/8 |
| Hemoglobin decreasedInvestigations | 0/14 | 0/14 | 1/8 |
| Fluid retentionMetabolism and nutrition disorders | 0/14 | 0/14 | 1/8 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 1/14 | 0/14 | 1/8 |
| Pulmonary edemaRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 1/8 |
| Age, Categorical(Participants) | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg | Total |
|---|---|---|---|---|
| <=18 years | 14 | 14 | 8 | 36 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(weeks) | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg | Total |
|---|---|---|---|---|
| Mean | 1.637 ± 1.8290 | 1.098 ± 1.0849 | 2.225 ± 1.5779 | 1.558 ± 1.5382 |
| Age, Customized(Participants) | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg | Total |
|---|---|---|---|---|
| = 28 weeks to < 36 weeks gestational age | 6 | 6 | 0 | 12 |
| >= 36 weeks to <= 44 weeks gestational age | 8 | 8 | 8 | 24 |
| Sex: Female, Male(Participants) | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg | Total |
|---|---|---|---|---|
| Female | 6 | 6 | 0 | 12 |
| Male | 8 | 8 | 8 | 24 |
| Race (NIH/OMB)(Participants) | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 10 | 10 | 6 | 26 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 3 | 3 | 2 | 8 |
| Region of Enrollment(participants) | Dexmedetomidine 0.05 mcg/kg | Dexmedetomidine 0.1 mcg/kg | Dexmedetomidine 0.2 mcg/kg | Total |
|---|---|---|---|---|
| United States | 14 | 14 | 8 | 36 |
The record gives a start of Jul 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 3 years 4 months after primary completion. A results delay was requested in Sep 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Hospira, now a wholly owned subsidiary of Pfizer →